目的 探討康婦靈片聯(lián)合甲硝唑呋喃唑酮栓治療慢性宮頸炎的臨床療效。方法 選取2020年7月—2022年5月南陽市中心醫(yī)院婦科收治的116例慢性宮頸炎患者，按照隨機數(shù)字表法分為對照組和治療組，每組各58例。對照組患者給予陰道外用甲硝唑呋喃唑酮栓，用一次性手套將藥栓置入陰道后穹窿部位，睡前用藥，1枚/次，隔日1次。治療組在對照組的基礎(chǔ)上口服康婦靈片，3片/次，3次/d。兩組均連續(xù)用藥7 d。觀察兩組的臨床療效，比較兩組生活質(zhì)量評分量表（ST-36）評分、臨床癥狀改善時間、氧化應(yīng)激反應(yīng)和血清炎癥因子水平。結(jié)果 治療后，治療組患者總有效率是98.27%，顯著高于對照組的82.76%（P＜0.05）。治療后，治療組出現(xiàn)陰道分泌物增多、不規(guī)則陰道出血、外陰瘙癢、下腹酸痛等癥狀改善時間均顯著短于對照組（P＜0.05）。治療后，兩組患者SF-36評分均較治療前顯著升高（P＜0.05），治療后，治療組SF-36評分高于對照組（P＜0.05）。治療后，兩組超氧化物歧化酶（SOD）、一氧化氮（NO）水平均較治療前顯著升高，丙二醛（MDA）、血漿內(nèi)皮素（ET-1）水平顯著降低（P＜0.05）；治療后，治療組SOD、NO水平高于對照組，MDA、ET-1水平低于對照組（P＜0.05）。治療后，兩組白細胞介素-2（IL-2）、轉(zhuǎn)化生長因子-β（TGF-β）水平均較治療前顯著降低，血管內(nèi)皮生長因子（VEGF）、干擾素γ（IFN-γ）水平顯著升高（P＜0.05）；治療后，治療組血清因子水平改善優(yōu)于對照組（P＜0.05）。治療后，治療組不良反應(yīng)發(fā)生率是6.89%，顯著低于對照組的15.52%（P＜0.05）。結(jié)論 康婦靈片聯(lián)合甲硝唑呋喃唑酮栓治療慢性宮頸炎具有較好的臨床療效，可顯著提高患者生活質(zhì)量，有效調(diào)節(jié)機體氧化應(yīng)激反應(yīng)和炎性反應(yīng)，值得臨床推廣應(yīng)用。

Objective To investigate the clinical study of Kangfuling Tablets combined with Metronidazole and Furazolidone Suppositories in treatment of chronic cervicitis. Methods A total of 116 patients with chronic cervicitis admitted to the Department of Gynecology of Nanyang Central Hospital from July 2020 to May 2022 were selected and divided into control group and treatment group according to random number table method, with 58 cases in each group. Patients in the control group were given Metronidazole and Furazolidone Suppositories, use disposable gloves to put the suppository into the posterior fornix of the vagina before bed, 1 piece/time, once every other day. Patients in the treatment group were po administered with Kangfuling Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, the quality of Life Rating Scale (ST-36) score, clinical symptom improvement time, oxidative stress response and serum inflammatory factor levels were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 98.27%, which was significantly higher than that of the control group (82.76%, P< 0.05). After treatment, the improvement time of symptoms such as increased vaginal secretions, irregular vaginal bleeding, vulva pruritus and abdominal soreness in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, SF-36 scores in both groups were significantly higher than before treatment (P < 0.05), and after treatment, SF-36 scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, the levels of superoxide dismutase (SOD) and nitric oxide (NO) in 2 groups were significantly increased compared with before treatment, while malondialdehyde (MDA) and plasma endothelin (ET-1) were significantly decreased (P < 0.05). After treatment, SOD and NO levels in the treatment group were higher than those in the control group, MDA and ET-1 were lower than those in the control group (P < 0.05). After treatment, the levels of interleukin-2 (IL-2) and transforming growth factor-β (TGF-β) were significantly decreased, while the levels of vascular endothelial growth factor (VEGF) and interferon γ (IFN-γ) were significantly increased in both groups (P < 0.05). After treatment, the improvement of serum factor level in treatment group was better than that in control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was 6.89%, significantly lower than that in the control group (15.52%) (P < 0.05). Conclusion Kangfuling Tablets combined with Metronidazole and Furazolidone Suppositories has good clinical effect in treatment of chronic cervicitis, and can significantly improve the life quality of patients, effectively regulate the oxidative stress and inflammatory response of the body, which is worthy of clinical application.

R984

河南省科技發(fā)展計劃項目（182102311190）